KMDA Insider Trading: Officers Sell Stock Options May 14, 2026

Insider trading data reveals fascinating patterns about executive confidence in their companies. When officers and directors file initial ownership disclosures, it signals how much skin they have in the game. Today we examine two significant insider transactions at Kamada Ltd. (KMDA), a biopharmaceutical company with a market cap of $453.4 million. Both filings involve stock options, not direct share sales. VP General Counsel Livneh Nir and Director Botzer Uri reported holdings totaling $97,450 in combined option value. These initial ownership filings provide transparency into executive compensation and long-term incentive structures at the company.

Livneh Nir’s VP Stock Option Disclosure

Livneh Nir, serving as VP and General Counsel at KMDA, filed an initial ownership disclosure on March 13, 2026. The filing covered options to purchase 10,000 ordinary shares at $5.62 per share, valued at $56,200. This represents Nir’s first formal disclosure of equity holdings with the SEC.

Understanding Form 3 Filings

Form 3 filings are initial ownership statements required when insiders join a company or take on new roles. They establish a baseline of what executives own. Nir’s filing shows the company compensates its legal leadership through stock options. These options give executives the right to purchase shares at a fixed price, aligning their interests with shareholder value.

Option Valuation and Exercise Price

The $5.62 exercise price reflects the stock’s value when options were granted. Options become valuable if the stock price rises above this level. At current market conditions, these options represent meaningful compensation for Nir’s executive role. The 10,000-share grant is typical for C-suite legal positions at mid-cap biotech firms.

Botzer Uri’s Director Stock Option Holdings

Director Botzer Uri filed an initial ownership disclosure on April 16, 2026, covering a transaction dated December 22, 2026. The filing revealed employee stock options for 7,500 shares at $5.50 per share, totaling $41,250 in option value. This disclosure marks Uri’s first formal SEC filing as a board member.

Director Compensation Through Options

Board members at public companies receive equity compensation to ensure alignment with shareholders. Uri’s 7,500-share option grant is standard for independent directors. The $5.50 exercise price was set when the options were originally granted. Directors typically receive annual option grants as part of their board service compensation package.

Form 3 Filing Requirements for Directors

When directors join a board, they must file Form 3 within two business days of their appointment. Uri’s April filing disclosed holdings from December, indicating a delayed reporting or recent board appointment. The SEC filing provides complete details on Uri’s option holdings and vesting schedules.

What These Insider Transactions Signal

Both transactions are initial ownership filings, not active buying or selling. They represent baseline disclosures required by securities law. Together, the two insiders hold $97,450 in option value at KMDA. This combined equity stake shows management has financial incentives aligned with shareholder returns.

No Immediate Selling Pressure

These Form 3 filings do not indicate executives are selling shares. Options must be exercised before they become actual shares. The filings simply establish what compensation executives received. Investors should monitor future Form 4 filings to see if insiders exercise or sell these options.

Meyka AI Analysis

Meyka AI rates KMDA with a grade of B, reflecting solid fundamentals and sector performance. Insider equity holdings support management’s confidence in the company’s direction. These option grants are typical for biotech firms seeking to retain experienced executives and board talent.

Key Takeaways for KMDA Investors

Insider transactions at KMDA show two executives with meaningful equity stakes. Livneh Nir’s 10,000-share option grant and Botzer Uri’s 7,500-share grant total $97,450 in combined value. Both filings are initial ownership disclosures required by SEC rules. These transactions do not signal immediate selling or buying activity.

Monitoring Future Filings

Investors should watch for Form 4 filings if either executive exercises or sells options. Form 4 filings report actual transactions and must be filed within two business days. Option exercises or sales would indicate management’s confidence or concerns about stock price direction. Initial Form 3 filings are baseline disclosures, not trading signals.

Understanding Executive Compensation

Stock options align executive interests with long-term shareholder value. When executives hold options, they benefit from stock price appreciation. KMDA’s use of options for both officers and directors is standard practice in the biopharmaceutical sector.

Final Thoughts

Kamada Ltd. insiders Livneh Nir and Botzer Uri filed initial ownership disclosures totaling $97,450 in stock option value. These Form 3 filings establish baseline equity holdings for the VP General Counsel and Director respectively. The transactions represent compensation grants, not active buying or selling. Investors should monitor future Form 4 filings for actual option exercises or share sales. KMDA’s insider equity structure demonstrates management alignment with shareholder interests, supporting the company’s B-grade rating from Meyka AI.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.